Randomized AmnioFix Study During Radical Prostatectomy

Inclusion Criteria:

1. Male subjects between the ages 35-75
2. Primary diagnosis of prostate cancer selected for surgical intervention by one of the six protocol surgeons (Chapin, Davis, Matin, Pettaway, Pisters, Ward).
3. Have a willingness to comply with follow-up HRQOL (health related quality of life) surveys and PSA assessments.
4. Have ability to provide full written consent.
5. Primary diagnosis of untreated with clinically localized prostate cancer with Gleason score of 6, 7,8 or 9.
6. Planned elective radical prostatectomy with bilateral nerve sparing technique that can include high or low fascia.
7. Negative urinalysis within 30 days prior to date of surgery

Exclusion Criteria:

1. High-risk cancer planned for neoadjuvant therapy, full or partial excision of one or both neurovascular bundles.
2. Has any condition(s), which seriously compromises the subject's ability to participate in this study, sign consent, or has a known history of poor adherence with medical treatment.
3. Is unable to comply with learning and documenting penile rehabilitation, including oral 5-phosphodiesterase inhibitor use, vacuum pump therapy use, and/or injectable medications.
4. In the opinion of the PI, has a history of drug or alcohol abuse within last 12 months.
5. Is allergic to Aminoglycoside antibiotics (such as Gentamicin and/or Streptomycin).
6. Patients with a history of more than two weeks treatment with immuno-suppressants (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.
7. Patients currently enrolled in another study. Concurrent enrollment in another study is prohibited expect for the control arm which can be used for other protocols with HRQOL endpoints with similar instruments.
8. Has had prior hormonal therapy such as Lupron or oral anti-androgens.
9. Unwilling to participate in follow-up clinical appointments at MDACC.